This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Case Western Reserve University. Active years: 2014-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mayfield Heights, OH (US) (2014)
- Cleveland, OH (US) (2018 - 2019)
Company Filing History:
Years Active: 2014-2019
Title: The Innovative Work of Akiko Maeda in Ocular Disorder Treatment
Introduction:
Akiko Maeda, a talented inventor based in Cleveland, OH, has made significant contributions to the field of ocular disorder treatment. With a total of 4 patents to his name, Maeda has been at the forefront of developing novel methods to address eye-related health issues.
Latest Patents:
Maeda's latest patents showcase his expertise in systems pharmacology for treating ocular disorders. One of his patented inventions involves administering subtherapeutic amounts of agents to inhibit or block the activation of specific protein-coupled receptors in ocular cells. Another patent focuses on treating ocular disorders associated with aberrant all-trans-retinal clearance in the retina by administering primary amine compounds.
Career Highlights:
Throughout his career, Akiko Maeda has been associated with esteemed institutions such as Case Western Reserve University and Case Western University. His research and innovations have garnered recognition in the medical community for their potential to revolutionize the treatment of ocular disorders.
Collaborations:
In his research endeavors, Maeda has collaborated with notable individuals in the field, including Krzysztof Palczewski and Marcin Golczak. These partnerships have played a crucial role in advancing the understanding of ocular diseases and developing effective treatment strategies.
Conclusion:
Akiko Maeda's inventive spirit and dedication to improving ocular health have positioned him as a leading figure in the field of ophthalmology. His groundbreaking patents and collaborations underscore his commitment to innovation and excellence in addressing complex eye-related challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
